The aim of studying and bibliography

The main aim of study: The main objective of the module is to introduce students with selected issues of biotechnology drugs.

The general information about the module: The module includes 15 hours of lectures and 15 hours of seminars .

Bibliography required to complete the module

Bibliography used during lectures

1

O.Kayser

Podstawy biotechnologii farmaceutycznej

Wydawnictwo Uniwersytetu Jagiellońskiego.

2006

Bibliography used during classes/laboratories/others

1

Najnowsza literatura - prace przeglądowe i eksperymentalne

.

Bibliography to self-study

1

red.nauk. Alfred Zejc ; red.nauk. Maria Gorczyca ; aut. Hanna Byrtus [i in.].

Chemia leków : podręcznik dla studentów farmacji i farmaceutów

Warszawa : Wydawnictwo Lekarskie PZWL..

2008

Basic requirements in category knowledge/skills/social competences

Formal requirements: Registration for the present semester

Basic requirements in category knowledge: Knowledge of organic chemistry, cell biology and basics of biotechnology.

Basic requirements in category skills: The ability to self-education, search scientific articles in scientific databases, computer skills, performing a presentation in PowerPoint.

Basic requirements in category social competences: Ability to work in a group, performance multimedia presentations.

Module outcomes

MEK	The student who completed the module	Types of classes / teaching methods leading to achieving a given outcome of teaching	Methods of verifying every mentioned outcome of teaching	Relationships with KEK	Relationships with PRK
01	knows the basic methods for the production of drugs by biotechnological methods, method of testing drugs before allowing for clinical use, understand the mechanisms of action in the body	lecture	Written exam	K_W04++ K_W07+	P7S_WG
02	can yourself acquire knowledge about creation and production of biotech drugs, know how to present their knowledge	seminar	project presentation	K_U05+++ K_K01++	P7S_KK P7S_UU

Attention: Depending on the epidemic situation, verification of the achieved learning outcomes specified in the study program, in particular credits and examinations at the end of specific classes, can be implemented remotely (real-time meetings).

The syllabus of the module

Sem.	TK	The content	realized in	MEK
2	TK01	-	W01, W02	MEK01
2	TK02	-	W03, W04	MEK01
2	TK03	-	W05, W06	MEK01
2	TK04	-	W07, W08	MEK01
2	TK05	-	W09, W10	MEK01
2	TK06	-	W11, W12	MEK01
2	TK07	-	W13, W14	MEK01
2	TK08	Exam	W15	MEK01
2	TK09	Production and isolation of antibiotics	Ćw01, Ćw02, Ćw03	MEK02
2	TK10	Proteins and nucleic acids as medicaments	Ćw04, Ćw05, Ćw06	MEK02
2	TK11	Immunosuppressive drugs with neuroprotective potential	Ćw07, Ćw08, Ćw09	MEK02
2	TK12	Vaccines production	Ćw10, Ćw11, Ćw12, Ćw13	MEK02
2	TK13	The newest trends in the design of drugs	Ćw14, Ćw15	MEK02

The student's effort

The type of classes	The work before classes	The participation in classes	The work after classes
Lecture (sem. 2)	The preparation for a test: 5.00 hours/sem.	contact hours: 15.00 hours/sem.
Class (sem. 2)	The preparation for a Class: 10.00 hours/sem.	contact hours: 15.00 hours/sem.
Advice (sem. 2)	The preparation for Advice: 1.00 hours/sem.	The participation in Advice: 2.00 hours/sem.
Credit (sem. 2)	The preparation for a Credit: 10.00 hours/sem.	The written credit: 1.00 hours/sem. The oral credit: 1.00 hours/sem.

The way of giving the component module grades and the final grade

The type of classes	The way of giving the final grade
Lecture	Written Exam. Written exam, single-choice test, about 30 questions in the sheet. Student can get 1 point for each correct answer.51-60% (3); 61-70% (+3); 71-80% (4); 81-90 (+4); 91-100% (5)
Class	Project presentation in presentation form. Presentation shorter than 15 minutes, based on Polish-language literature - maximum grade 3. Presentation of at least 20 minutes, based on Polish-language literature - maximum grade 4. Fluently delivered, 20-minute presentation based on the latest English-language materials - grade 5.
The final grade	The final grade: (K): K = 0,5wC + 0,5wE; where: C, E is possitive grade from discussions and exam, w - term of test or exam coefficient, w = 1,0 the first term, w = 0,9 the second term, w = 0,8 the third term.

Sample problems

Required during the exam/when receiving the credit
(-)

Realized during classes/laboratories/projects
(-)

Others
(-)

Can a student use any teaching aids during the exam/when receiving the credit : no

The contents of the module are associated with the research profile: yes

1	M. Misiorek; N. Pieńkowska; M. Siorek; Ż. Szymaszek; M. Twardowska; Ł. Uram; S. Wołowiec	Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents—Comparative Studies on Normal and Immortalized Cell Lines, and on C. elegans	2024
2	K. Balawender; K. Bulanda; K. Kroczek; B. Lewandowski; M. Oleksy; S. Orkisz; M. Potoczek; J. Szczygielski; Ł. Uram	Polylactide-based composites with hydroxyapatite used in rapid prototyping technology with potential for medical applications	2023
3	Ż. Szymaszek; M. Twardowska; Ł. Uram; M. Walczak; S. Wołowiec; K. Wróbel	Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment	2023
4	J. Markowicz; W. Rode; Ł. Uram; S. Wołowiec	Synthesis and Properties of α-Mangostin and Vadimezan Conjugates with Glucoheptoamidated and Biotinylated 3rd Generation Poly(amidoamine) Dendrimer, and Conjugation Effect on Their Anticancer and Anti-Nematode Activities	2022
5	J. Markowicz; Ł. Uram; E. Wałajtys-Rode; S. Wołowiec; K. Wróbel	Synthesis of Biotinylated PAMAM G3 Dendrimers Substituted with R-Glycidol and Celecoxib/Simvastatin as Repurposed Drugs and Evaluation of Their Increased Additive Cytotoxicity for Cancer Cell Lines	2022
6	J. Markowicz; W. Rode; Ł. Uram; S. Wołowiec	Biotin Transport-Targeting Polysaccharide-Modified PAMAM G3 Dendrimer as System Delivering α-Mangostin into Cancer Cells and C. elegans Worms	2021
7	M. Dąbrowska; M. Dąbrowski; E. Sikora; Ł. Uram	Antigen presentation capability and AP-1 activation accompany methotrexate-induced colon cancer cell senescence in the context of aberrant β-catenin signaling	2021
8	M. Malinga-Drozd; Ł. Uram; S. Wołowiec; K. Wróbel	Chiral Recognition of Homochiral Poly (amidoamine) Dendrimers Substituted with R- and S-Glycidol by Keratinocyte (HaCaT) and Squamous Carcinoma (SCC-15) Cells In Vitro	2021
9	A. Filipowicz-Rachwał; J. Markowicz; M. Misiorek; Ł. Uram; E. Wałajtys-Rode; S. Wołowiec	Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent	2020
10	B. Botta; A. Calcaterra; Y. Cau; P. Maj; J. Markowicz; M. Mori; D. Quaglio ; W. Rode; J. Sobich; Ł. Uram; Z. Zieliński	Alvaxanthone, a Thymidylate Synthase Inhibitor with Nematocidal and Tumoricidal Activities	2020
11	B. Król; P. Król; K. Pielichowska; M. Sochacka-Piętal; Ł. Uram; M. Walczak	Synthesis and property of polyurethane elastomer for biomedical applications based on nonaromatic isocyanates, polyesters, and ethylene glycol	2020
12	E. Chmiel; A. Czerniecka-Kubicka; M. Misiorek; M. Pyda; P. Tutka; Ł. Uram; M. Walczak; S. Wołowiec	Stepwise glucoheptoamidation of poly(amidoamine) dendrimer G3 to tune physicochemical properties of the potential drug carrier: in vitro tests for cytisine conjugates	2020
13	J. Czarnik-Kwaśniak; I. Filiks; K. Kwaśniak; M. Stompor; K. Tutaj; Ł. Uram; S. Wołowiec	Glucoheptoamidated polyamidoamine PAMAM G3 dendrimer as a vehicle for succinate linked doxorubicin; enhanced toxicity of DOX against grade IV glioblastoma U-118 MG cells	2020
14	A. Filipowicz-Rachwał; J. Markowicz; M. Misiorek; M. Pichla; Ł. Uram; E. Wałajtys-Rode; S. Wołowiec	The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro	2019
15	A. Filipowicz-Rachwał; M. Misiorek; Ł. Uram; E. Wałajtys-Rode; A. Winiarz; S. Wołowiec	Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimer Substituted with Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells	2019
16	A. Filipowicz-Rachwał; M. Szuster; Ł. Uram; E. Wałajtys-Rode; S. Wołowiec	Evaluation of the localization and biological effects of PAMAM G3 dendrimer-biotin/pyridoxal conjugate as HaCaT keratinocyte targeted nanocarrier	2019
17	D. Aebisher; A. Białońska; M. Kopaczyńska; P. Sareło; Ł. Uram; M. Walczak; S. Wołowiec; M. Zaręba	Mixed-Generation PAMAM G3-G0 Megamer as a Drug Delivery System for Nimesulide: Antitumor Activity of the Conjugate Against Human Squamous Carcinoma and Glioblastoma Cells	2019
18	M. Dąbrowska; W. Rode; M. Skoneczny; Ł. Uram	Methotrexate-induced senescence of human colon cancer cells depends on p53 acetylation, but not genomic aberrarions	2019
19	P. Maj; L. Mangiardi; J. Markowicz; W. Rode; J. Sobich; Ł. Uram	Antitumor and anti-nematode activities of α-mangostin	2019